Delicious
Digg
Facebook
LinkedIn
Twitter
- First quarter LINZESS® (linaclotide) net
product sales of
- Multi-channel Direct-to-Consumer awareness campaign launched -
"During the first fifteen months of the LINZESS launch, we have
established a strong foundation of physician experience and payer
coverage for LINZESS. Now, while we continue advancing with prescribers
and payers, we are intensifying our efforts to educate appropriate
patients about LINZESS through a multi-channel, direct-to-consumer
patient awareness campaign," said
First Quarter 2014 and Recent Highlights
LINZESS® (linaclotide)
-
LINZESS net product sales, as reported by Forest Laboratories, Inc.,
were
$60.8 million in the first quarter of 2014, an increase of approximately 19% quarter over quarter. -
Nearly 240,000 LINZESS prescriptions were filled in the first quarter
of 2014, according to IMS Health, resulting in approximately 11%
growth in total prescriptions quarter over quarter. More than 800,000
LINZESS prescriptions have been filled by more than 260,000 unique
adult patients since the product's launch in
December 2012 , according to IMS Health. - The total number of unique healthcare practitioners prescribing LINZESS since launch reached more than 63,000 in the first quarter of 2014, according to IMS Health. This includes approximately 92% of high prescribing gastroenterologists and approximately 76% of other high prescribing healthcare practitioners, mostly primary care physicians.
-
More than 70% of people with commercial insurance and
Medicare Part D plans had unrestricted access to LINZESS as ofMarch 2014 . Additionally, inMarch 2014 , more than 70% of people with commercial insurance had a copay of$30 or less, through formulary coverage or the LINZESS Instant Savings Program. - Ironwood and Forest launched a DTC patient awareness campaign for LINZESS designed to help adults suffering from IBS-C or CIC recognize the symptoms of these disorders, describe their symptoms to their doctor, and ask their doctor about LINZESS to help proactively manage their disease. The extensive multi-channel campaign includes television, print and online advertising; social media elements; an updated brand website (www.linzess.com); brochures in doctors' offices and pharmacies; and a waiting room TV program.
- Ironwood and Forest received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two separate patent applications covering the commercial formulation of LINZESS and methods of using the product to treat patients with IBS-C or CIC. Both of these patent applications are expected to issue in mid-2014 and extend LINZESS patent protection by an additional five years into 2031. In addition, Ironwood was successful in defending a separate linaclotide patent that was subject to an inter partes reexamination. The USPTO confirmed that all claims in the patent are patentable, concluding the review in Ironwood's favor and affirming the strength of Ironwood's intellectual property around LINZESS.
Linaclotide (Rest of World)
-
Almirall, S.A., Ironwood's European partner, continues to
commercialize CONSTELLA® (linaclotide) in
Europe , where it is the first and only prescription product approved by theEuropean Medicines Agency for the symptomatic treatment of moderate to severe IBS-C in adult patients.CONSTELLA has been approved for adult patients with moderate to severe IBS-C and has been launched in 10 countries inEurope , including theUnited Kingdom ,Germany and most recentlyItaly , with additional country launches expected in 2014. Almirall recently announced that it intends to suspend commercialization ofCONSTELLA inGermany inMay 2014 , following an inability to reach agreement with theGerman National Association of Statutory Health Insurance Funds on a reimbursement price that reflects the innovation and value ofCONSTELLA . Almirall is assessing all possibilities to facilitate continued access toCONSTELLA for appropriate patients inGermany . -
Forest received marketing approval for linaclotide in
Canada andMexico ; launches in both countries are expected in mid-2014. Forest has the rights to commercializeCONSTELLA inCanada and, through a sublicense from Forest, Almirall has the rights to commercialize LINZESS inMexico . -
Ironwood and AstraZeneca AB continue to enroll patients in a Phase III clinical trial of linaclotide in adult patients with IBS-C inChina . The trial is expected to be completed in the first half of 2015. -
Astellas Pharma Inc. completed a Phase II double-blind,
placebo-controlled, dose-ranging clinical trial of linaclotide in
adult patients with IBS-C in
Japan . Preliminary top level data from Astellas indicate higher responder rates for all linaclotide dose groups versus placebo in the primary endpoint, although the difference was not statistically significant. Linaclotide was well tolerated in all dose groups within this study.
Research & Development
-
Ironwood continues to explore opportunities to evaluate linaclotide in
additional indications such as opioid-induced constipation, colorectal
cancer prevention, and pediatrics, as well as in combination with a
proton pump inhibitor and in a colonic delivery formulation. Ironwood
also is leveraging its gastrointestinal and guanylate cyclase
expertise to advance a robust pipeline of additional potential product
candidates, including IW‐3718 which is being studied for refractory
GERD, IW-9179 which is being studied for functional dyspepsia (FD) and
gastroparesis, and a soluble guanylate cyclase (sGC) program. Research
and development highlights for the quarter include:
- Ironwood initiated dosing of its investigational bile acid sequestrant, IW‐3718, in a Phase IIa clinical study for patients with GERD symptoms who have not responded adequately to treatment with a proton pump inhibitor. Data from this trial are expected in the first half of 2015.
- Ironwood ended its exploratory Phase IIa study of IW-9179 in FD prior to completing enrollment, due to challenges with the rigorous enrollment exclusion criteria in the trial. Data analysis is ongoing but preliminary data support continued development. Ironwood continues to define a path forward for IW-9179 in FD. In parallel, Ironwood plans to initiate a Phase IIa clinical trial of IW-9179 in patients with gastroparesis in the first half of 2015.
- Ironwood identified a development candidate in its sGC program, which targets a proven mechanism for treating pulmonary arterial hypertension (PAH) and other cardiovascular diseases with the potential for broad therapeutic utility both inside and outside of the CV therapeutic category. Preclinical development is ongoing.
Corporate and Financials
-
Collaborative Arrangements Revenue. Collaborative arrangements
revenue was approximately
$14.6 million in the first quarter of 2014 compared with approximately$5.0 million in the fourth quarter of 2013. The collaborative arrangements revenue consisted of$8.4 million in revenue associated with Ironwood's share of the net profits and losses from the sales of LINZESS in the U.S., as well as$6.2 million in sales of linaclotide active pharmaceutical ingredient (API), amortization of deferred revenue associated with consideration received from Ironwood's collaboration with Astellas, revenue recognized under the collaboration with AstraZeneca, and milestone and royalty payments based on sales ofCONSTELLA inEurope from Almirall.
-
Operating Expenses. Operating expenses were approximately
$57.1 million in the first quarter of 2014, including non-reoccurring charges totaling$4.3 million associated with Ironwood's headcount reduction inJanuary 2014 , as compared to approximately$51.2 million in the fourth quarter of 2013. Operating expenses consisted of approximately$27.1 million in research and development (R&D) expenses, which included$2.7 million in non-cash share-based compensation expense, and approximately$30.0 million in selling, general and administrative (SG&A) expenses, which included$3.4 million in non-cash share-based compensation expense. -
Collaboration Expense. Ironwood records its share of the net
profits and losses from the sales of LINZESS in the U.S. on a net
basis and presents the settlement payments from and to Forest as
collaborative arrangements revenue or collaboration expense,
respectively. In the first quarter of 2014 and the fourth quarter of
2013, Ironwood recorded the settlement payments from Forest of
approximately
$8.4 million and$2.9 million , respectively, as collaborative arrangements revenue, and no collaboration expense was recorded. -
Interest Expense. Interest expense was approximately
$5.3 million in the first quarter of 2014 in connection with the$175 million debt financing executed inJanuary 2013 . -
Net Loss. Net loss was approximately
$49.6 million , or$0.38 per share, in the first quarter of 2014, as compared to approximately$52.0 million , or$0.43 per share, in the fourth quarter of 2013. -
Cash Position. Ironwood ended the first quarter of 2014 with
approximately
$332 million of cash, cash equivalents and available-for-sale securities, up from approximately$198 million as of the end of 2013. Ironwood used approximately$58 million of cash for operations during the first quarter of 2014. -
Public Equity Offering. In the first quarter of 2014, Ironwood
sold 15,784,325 shares of its Class A common stock through a firm
commitment, underwritten public offering at a price to the public of
$12.75 per share. As a result of the offering, Ironwood received aggregate net proceeds, after underwriting discounts and commissions and other offering expenses, of approximately$190.4 million . -
2014 Financial Guidance. Ironwood today reiterated its
financial guidance for 2014. Total operating expenses are expected to
be in the range of
$215 to$245 million , consisting of$105 to$120 million in R&D expenses and$110 to$125 million in SG&A expenses. Non-linaclotide R&D expenses are expected to be approximately 45% of total R&D expenses. In addition, Ironwood today reiterated its financial guidance for the Forest and Ironwood total 2014 marketing and sales expenses for LINZESS, which it continues to expect to be in the range of$240 to$270 million .
Conference Call Information
Ironwood will host a conference call and webcast at
About LINZESS (linaclotide)
LINZESS is the first and only guanylate cyclase-C (GC-C) agonist
approved by the
LINZESS is thought to work in two ways based on nonclinical studies. LINZESS binds to the GC-C receptor locally, within the intestinal epithelium. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established.
In placebo-controlled Phase III clinical trials of more than 2,800 adults, LINZESS was shown to reduce abdominal pain in IBS-C patients and increase bowel movement frequency in both IBS-C patients and CIC patients. Improvement in abdominal pain and constipation occurred in the first week of treatment and was maintained throughout the 12-week treatment period. Maximum effect on abdominal pain was seen at weeks 6-9 and maximum effect on constipation occurred during the first week. When a subset of LINZESS-treated patients in the trials were switched to placebo, they reported their symptoms returned toward pretreatment levels within one week, while placebo-treated patients switched to LINZESS reported symptom improvements. LINZESS is contraindicated in pediatric patients up to 6 years of age. The use of LINZESS in pediatric patients 6 through 17 years of age should be avoided. In nonclinical studies, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths in young juvenile mice. LINZESS has not been studied in pediatric patients. In adults with IBS-C or CIC treated with LINZESS, the most commonly reported adverse event was diarrhea.
About
Linaclotide is a Guanylate Cyclase-C receptor agonist (GCCA) with visceral analgesic and secretory activities. Linaclotide is a 14-amino acid synthetic peptide structurally related to the endogenous guanylin peptide family. Both linaclotide and its active metabolite bind to the Guanylate Cyclase-C receptor, on the luminal surface of the intestinal epithelium. Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans. Activation of GC-C results in an increase in concentrations of cyclic guanosine monophosphate (cGMP), both extracellularly and intracellularly. Extracellular cGMP decreases pain-fiber activity, resulting in reduced visceral pain in animal models. Intracellular cGMP causes secretion of chloride and bicarbonate into the intestinal lumen, through activation of the cystic fibrosis transmembrane conductance regulator (CFTR), which results in increased intestinal fluid and accelerated transit.
Linaclotide was discovered by scientists at Ironwood and is marketed by
Almirall, S.A. for the treatment of adults with moderate to severe IBS-C
in
About
LINZESS® and CONSTELLA® are trademarks owned by
Important Safety Information
|
WARNING: PEDIATRIC RISK
LINZESS is contraindicated in pediatric patients up to 6 years of age. Use should be avoided in pediatric patients 6 through 17 years of age. In nonclinical studies, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths in young juvenile mice. |
Contraindications
- LINZESS is contraindicated in pediatric patients up to 6 years of age.
- LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Pediatric Risk
- LINZESS is contraindicated in pediatric patients up to 6 years of age. In nonclinical studies, deaths occurred within 24 hours in young juvenile mice (1 to 3 week-old mice; approximately equivalent to human pediatric patients less than 2 years of age) following administration of one or two daily oral doses of linaclotide.
- Use of LINZESS should be avoided in pediatric patients 6 through 17 years of age. Linaclotide did not cause deaths in older juvenile mice (approximately equivalent to humans age 12 to 17 years). Although there were no deaths in older juvenile mice, given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, use of LINZESS should be avoided in pediatric patients 6 through 17 years of age.
Diarrhea
- Diarrhea was the most common adverse reaction of LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. Severe diarrhea was reported in 2% of LINZESS-treated patients. The incidence of diarrhea was similar in the IBS-C and CIC populations.
- Patients should be instructed to stop LINZESS if severe diarrhea occurs and to contact their healthcare provider, who should consider dose suspension.
Adverse Reactions
- In IBS-C clinical trials, the most common adverse reactions in LINZESS-treated patients (incidence ≥2% and greater than placebo) were diarrhea (20% vs 3% placebo), abdominal pain (7% vs 5%), flatulence (4% vs 2%), headache (4% vs 3%), viral gastroenteritis (3% vs 1%) and abdominal distension (2% vs 1%).
- In CIC clinical trials, the most common adverse reactions in LINZESS-treated patients (incidence ≥2% and greater than placebo) were diarrhea (16% vs 5% placebo), abdominal pain (7% vs 6%), flatulence (6% vs 5%), upper respiratory tract infection (5% vs 4%), sinusitis (3% vs 2%) and abdominal distension (3% vs 2%).
Please see full Prescribing Information including Boxed Warning: http://www.frx.com/pi/linzess_pi.pdf.
This press release contains forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking
statements, including, but not limited to, statements about our
development and commercialization plans for linaclotide, our product
candidates and the programs in our pipeline, including statements
regarding our LINZESS patient awareness campaign; the launch and
commercialization of linaclotide in additional countries and the timing
thereof, as well as expectations regarding the continued
commercialization of
|
Condensed Consolidated Balance Sheets (In thousands) (unaudited) |
|||||||||||
|
2014 |
2013 |
||||||||||
| Assets | |||||||||||
| Cash, cash equivalents and available-for-sale securities | $ | 332,269 | $ | 197,602 | |||||||
| Accounts receivable, net | 10,337 | 3,213 | |||||||||
| Inventory | 23,413 | 22,145 | |||||||||
| Prepaid expenses and other current assets | 5,286 | 6,168 | |||||||||
| Total current assets | 371,305 | 229,128 | |||||||||
| Property and equipment, net | 35,524 | 37,376 | |||||||||
| Other assets | 12,042 | 12,458 | |||||||||
| Total assets | $ | 418,871 | $ | 278,962 | |||||||
| Liabilities and Stockholders' Equity | |||||||||||
| Accounts payable and accrued expenses | $ | 24,032 | $ | 32,037 | |||||||
| Current portion of capital lease obligations | 1,156 | 1,139 | |||||||||
| Current portion of deferred rent | 2,803 | 2,790 | |||||||||
| Current portion of deferred revenue | 6,128 | 5,074 | |||||||||
| Current portion of notes payable | 4,381 | — | |||||||||
| Total current liabilities | 38,500 | 41,040 | |||||||||
| Capital lease obligations | 2,842 | 3,134 | |||||||||
| Deferred rent | 8,127 | 8,822 | |||||||||
| Deferred revenue | 10,147 | 11,416 | |||||||||
| Notes payable | 170,312 | 174,672 | |||||||||
| Other liabilities | — | 1,653 | |||||||||
| Total stockholders' equity | 188,943 | 38,225 | |||||||||
| Total liabilities and stockholders' equity | $ | 418,871 | $ | 278,962 | |||||||
|
Condensed Consolidated Statements of Operations (In thousands, except per share amounts) (unaudited) |
||||||||||||
|
|
||||||||||||
|
Three Months Ended
|
||||||||||||
| 2014 | 2013 | |||||||||||
| Revenue | $ | 14,605 | $ | 3,255 | ||||||||
| Cost and expenses: | ||||||||||||
| Cost of revenue | 1,924 | 1,231 | ||||||||||
| Research and development (1) | 27,144 | 32,753 | ||||||||||
| Selling, general and administrative (1) | 29,924 | 33,374 | ||||||||||
| Collaboration expense | — | 24,730 | ||||||||||
| Total cost and expenses | 58,992 | 92,088 | ||||||||||
| Loss from operations | (44,387 | ) | (88,833 | ) | ||||||||
| Other income (expense), net | (5,239 | ) | (5,069 | ) | ||||||||
| Net loss | $ | (49,626 | ) | $ | (93,902 | ) | ||||||
| Net loss per share—basic and diluted | $ | (0.38 | ) | $ | (0.87 | ) | ||||||
|
Weighted average number of common shares used in net loss per
share — |
129,745 | 108,073 | ||||||||||
|
(1) Non-cash compensation expenses reflected in the condensed |
|
|
||||||||||
|
Research and development |
$ |
2,690 |
$ |
2,224 |
||||||||
|
Selling, general and administrative |
$ |
3,384 |
$ |
3,051 |
||||||||
|
LINZESS U.S. Collaboration Revenue/Expense Calculation1 (in thousands) (unaudited) |
|||||||||||
|
Three Months Ended
|
|||||||||||
| 2014 | 2013 | ||||||||||
| LINZESS net sales | $ | 60,812 | $ | 4,502 | |||||||
|
Commercial costs and expenses2 |
59,916 | 71,040 | |||||||||
| Net profit (loss) on sales of LINZESS | $ | 896 | $ | (66,538 | ) | ||||||
| Ironwood's share of net profit (loss) | $ | 448 | $ | (33,269 | ) | ||||||
|
Ironwood's selling, general and administrative expenses3 |
$ | 7,999 | $ | 8,539 | |||||||
| Ironwood's collaboration expense | $ | — | $ | (24,730 | ) | ||||||
| Ironwood's collaborative arrangement revenue | $ | 8,447 | $ | — | |||||||
1 Ironwood collaborates with Forest on the development and
commercialization of linaclotide in
2 Includes cost of goods sold incurred by Forest as well as selling, general and administrative expenses incurred by Forest and Ironwood that are attributable to the cost-sharing arrangement between the parties.
3 Includes Ironwood's selling, general and administrative expenses attributable to the cost-sharing arrangement with Forest.
Media Relations
Associate Director, Corporate Communications
tmorrison@ironwoodpharma.com
or
Investor
Relations
Investor Relations
mconway@ironwoodpharma.com
Source:
News Provided by Acquire Media
